High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
Biomarker
CXCL10
Fibrosis
ILD
Inflammation
Systemic sclerosis
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
22 Nov 2023
22 Nov 2023
Historique:
received:
04
05
2023
revised:
26
10
2023
accepted:
06
11
2023
medline:
24
11
2023
pubmed:
24
11
2023
entrez:
23
11
2023
Statut:
aheadofprint
Résumé
Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of death in patients with SSc. There is an unmet need for predictive biomarkers to identify patients with SSc at risk of ILD. Previous studies have shown that interferon (IFN) pathways may play a role in SSc. We assessed the use of C-X-C motif chemokine ligand 10 (CXCL10) as a predictive biomarker for new onset of ILD in patients with SSc. One-hundred-sixty-five (Female, N = 130) patients with SSc (SSc-ILD, N = 41) and 13 (Female, N = 8) healthy controls were investigated retrospectively. CXCL10 protein levels were measured by ELISA. We performed log rank analysis with baseline CXCL10 serum levels. CXCL10 nanoString data from lung tissues obtained from transplanted patients with SSc-ILD were extracted. Fifteen (Female, N = 10) patients with SSc (SSc-ILD, N = 7) were recruited for bronchoalveolar lavage (BAL) procedure. Lung fibroblasts were treated with BAL-fluid or serum from patients with SSc with or without ILD. Inflammatory/fibrotic genes were assessed. Serum CXCL10 levels were higher in patients with SSc-ILD compared to SSc patients without ILD [Median (IQR):126 pg/ml (66-282.5) vs. 78.5 pg/ml (50-122), P = 0.029, 95% CI: 1.5 × 10 Clinical, transcriptomic, and in vitro data showed that CXCL10 is potentially involved in early SSc-ILD. More research is needed to confirm whether CXCL10 can be classified as a prospective biomarker to detect patients with SSc at higher risk of developing new onset ILD. This collaborative project is co-financed by the Ministry of Economic Affairs and Climate Policy of the Netherlands utilizing the PPP-allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships (PPP-2019_007). Part of this study is financially supported by Sanofi Genzyme (NL8921).
Sections du résumé
BACKGROUND
BACKGROUND
Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of death in patients with SSc. There is an unmet need for predictive biomarkers to identify patients with SSc at risk of ILD. Previous studies have shown that interferon (IFN) pathways may play a role in SSc. We assessed the use of C-X-C motif chemokine ligand 10 (CXCL10) as a predictive biomarker for new onset of ILD in patients with SSc.
METHODS
METHODS
One-hundred-sixty-five (Female, N = 130) patients with SSc (SSc-ILD, N = 41) and 13 (Female, N = 8) healthy controls were investigated retrospectively. CXCL10 protein levels were measured by ELISA. We performed log rank analysis with baseline CXCL10 serum levels. CXCL10 nanoString data from lung tissues obtained from transplanted patients with SSc-ILD were extracted. Fifteen (Female, N = 10) patients with SSc (SSc-ILD, N = 7) were recruited for bronchoalveolar lavage (BAL) procedure. Lung fibroblasts were treated with BAL-fluid or serum from patients with SSc with or without ILD. Inflammatory/fibrotic genes were assessed.
FINDINGS
RESULTS
Serum CXCL10 levels were higher in patients with SSc-ILD compared to SSc patients without ILD [Median (IQR):126 pg/ml (66-282.5) vs. 78.5 pg/ml (50-122), P = 0.029, 95% CI: 1.5 × 10
INTERPRETATIONS
CONCLUSIONS
Clinical, transcriptomic, and in vitro data showed that CXCL10 is potentially involved in early SSc-ILD. More research is needed to confirm whether CXCL10 can be classified as a prospective biomarker to detect patients with SSc at higher risk of developing new onset ILD.
FUNDING
BACKGROUND
This collaborative project is co-financed by the Ministry of Economic Affairs and Climate Policy of the Netherlands utilizing the PPP-allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships (PPP-2019_007). Part of this study is financially supported by Sanofi Genzyme (NL8921).
Identifiants
pubmed: 37995465
pii: S2352-3964(23)00449-8
doi: 10.1016/j.ebiom.2023.104883
pmc: PMC10708993
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104883Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests D.J. Mulder received grants from Sanofi Genzyme paid to the institution. W. Timens received consultancy fees from Merck Sharp Dohme and Bristol-Myers Squibb. The rest of the coauthors declare no conflict of interest.
Références
Eur Respir Rev. 2015 Sep;24(137):411-9
pubmed: 26324802
PLoS One. 2020 Nov 2;15(11):e0241719
pubmed: 33137121
J Rheumatol. 2018 Aug;45(8):1153-1158
pubmed: 29961690
Int J Mol Sci. 2021 Mar 12;22(6):
pubmed: 33809279
J Pathol. 2008 Jan;214(2):199-210
pubmed: 18161745
Eur Respir J. 2001 Jun;17(6):1220-7
pubmed: 11491168
Immunol Cell Biol. 2011 Feb;89(2):207-15
pubmed: 21221121
Inflammation. 2021 Feb;44(1):206-216
pubmed: 32772240
Ann Rheum Dis. 2011 Nov;70(11):2029-36
pubmed: 21803750
Rev Med Interne. 2009 Nov;30(11):942-6
pubmed: 19577826
J Neuroinflammation. 2016 Aug 30;13(1):217
pubmed: 27576738
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
J Scleroderma Relat Disord. 2021 Feb;6(1):11-20
pubmed: 33693057
Ann Rheum Dis. 2018 Dec;77(12):1845-1846
pubmed: 29760155
Rheumatology (Oxford). 2008 Jan;47(1):45-9
pubmed: 18077490
Arthritis Rheum. 1997 Apr;40(4):743-51
pubmed: 9125259
Rheumatology (Oxford). 2023 Feb 1;62(2):535-545
pubmed: 35861385
Expert Rev Clin Immunol. 2019 Jul;15(7):753-764
pubmed: 31046487
Cytokine. 2017 Jun;94:45-51
pubmed: 28411045
Eur J Immunol. 2021 Jul;51(7):1615-1627
pubmed: 33930196
J Rheumatol. 2013 Apr;40(4):435-46
pubmed: 23378460
Antioxidants (Basel). 2023 Mar 24;12(4):
pubmed: 37107169
J Clin Endocrinol Metab. 2001 Oct;86(10):5008-16
pubmed: 11600578
Front Immunol. 2023 Jun 20;14:1189257
pubmed: 37409127
Arthritis Res Ther. 2018 Mar 22;20(1):52
pubmed: 29566745
Immunotherapy. 2021 Feb;13(3):241-256
pubmed: 33410346
Ann Rheum Dis. 2012 Jul;71(7):1235-42
pubmed: 22586157
Arthritis Rheumatol. 2021 May;73(5):858-865
pubmed: 33258553
Arthritis Res Ther. 2003;5(2):R74-81
pubmed: 12718750
J Transl Med. 2021 Apr 17;19(1):156
pubmed: 33865426
Autoimmun Rev. 2014 Mar;13(3):272-80
pubmed: 24189283
Front Immunol. 2019 May 15;10:1093
pubmed: 31156640
Front Immunol. 2013 Sep 06;4:266
pubmed: 24046769
Rheumatology (Oxford). 2017 Oct 1;56(10):1662-1675
pubmed: 28122959
Int J Mol Sci. 2022 Sep 05;23(17):
pubmed: 36077548
Respir Res. 2022 May 16;23(1):126
pubmed: 35578269
Front Immunol. 2018 Jan 15;8:1970
pubmed: 29379506
Nat Immunol. 2019 Dec;20(12):1574-1583
pubmed: 31745335
JCI Insight. 2022 Sep 8;7(17):
pubmed: 35943798
Arthritis Rheumatol. 2017 Dec;69(12):2359-2369
pubmed: 28859262
Nat Rev Immunol. 2017 Sep;17(9):559-572
pubmed: 28555670
Eur Respir J. 2020 May 14;55(5):
pubmed: 32079645
Biochem Pharmacol. 2020 Aug;178:114103
pubmed: 32562787
J Dermatol Sci. 2004 Jun;35(1):43-51
pubmed: 15194146
Rheumatology (Oxford). 2019 Sep 1;58(9):1534-1546
pubmed: 31292645
Diabetologia. 2002 Aug;45(8):1107-10
pubmed: 12189440
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
Am J Respir Crit Care Med. 2006 Feb 1;173(3):310-7
pubmed: 16239626
Front Med (Lausanne). 2018 Sep 25;5:271
pubmed: 30320116